Automated breast volume scanner based Radiomics for non-invasively prediction of lymphovascular invasion status in breast cancer.

PURPOSE: Lymphovascular invasion (LVI) indicates resistance to preoperative adjuvant chemotherapy and a poor prognosis and can only be diagnosed by postoperative pathological examinations in breast cancer. Thus, a technique for preoperative diagnosis of LVI is urgently needed. We aim to explore the ability of an automated breast volume scanner (ABVS)-based radiomics model to noninvasively predict the LVI status in breast cancer. METHODS: We conducted a retrospective analysis of data from 335 patients diagnosed with T1-3 breast cancer between October 2019 and September 2022. The patients were divided into training cohort and validation cohort with a ratio of 7:3. For each patient, 5901 radiomics features were extracted from ABVS images. Feature selection was performed using LASSO method. We created machine learning models for different feature sets with support vector machine algorithm to predict LVI. And significant clinicopathologic factors were identified by univariate and multivariate logistic regression to combine with three radiomics signatures as to develop a fusion model. RESULTS: The three SVM-based prediction models, demonstrated relatively high efficacy in identifying LVI of breast cancer, with AUCs of 79.00%, 80.00% and 79.40% and an accuracy of 71.00%, 80.00% and 75.00% in the validation cohort for AP, SP and CP plane image. The fusion model achieved the highest AUC of 87.90% and an accuracy of 85.00% in the validation cohort. CONCLUSIONS: The combination of radiomics features from ABVS images and an SVM prediction model showed promising performance for preoperative noninvasive prediction of LVI in breast cancer.

miR-328-5p inhibits MDA-MB-231 breast cancer cell proliferation by targeting RAGE.

MicroRNAs (miRNAs) are a class of short non-coding RNAs that play an important role in gene regulation and are critically involved in the pathogenesis and progression of human cancer. miR-328-5p has been reported to potentially act as a sensitising agent in breast cancer, but its other cellular functions and mechanisms remain unknown. The primary aim of the present study was to discover additional cellular functions and mechanisms of miR-328-5p in the breast cancer cell line MDA-MB-231. In the present study, miRNA microarray was used to find altered miRNAs. MTT and colony formation were used to test cell proliferation. Flow cytometry and western blotting were used to explore potential mechanisms of miR-328-5p regulating cell proliferation. A luciferase reporter assay was used to confirm target binding. miR-328-5p was revealed to be significantly upregulated after knockdown of the receptor for advanced glycosylation end products (RAGE). We also confirmed that miR-328-5p was frequently decreased in breast cancer tissues. Moreover, miR-328-5p mimics inhibited MDA-MB-231 proliferation, drug resistance and cell cycle progression. We confirmed that RAGE was a direct target of miR-328-5p. Functions of miR-328-5p in MDA-MB­231 cells were elucidated by targeting RAGE. In conclusion, these results revealed that miR-328-5p may be considered as a tumour-suppressor factor, and promoting miR-328-5p expression could be a novel therapeutic strategy for breast cancer.